{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T05:38:21Z","timestamp":1787981901109,"version":"build-2784847793"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12879-016-1384-7","type":"journal-article","created":{"date-parts":[[2016,1,27]],"date-time":"2016-01-27T17:00:42Z","timestamp":1453914042000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Analysis of drug treatment outcome in clarithromycin-resistant Mycobacterium avium complex lung disease"],"prefix":"10.1186","volume":"16","author":[{"given":"Tsukasa","family":"Kadota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotoshi","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Hirose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minako","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Akaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouichi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Akashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuhisa","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinobu","family":"Akagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Ohta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,1,27]]},"reference":[{"key":"1384_CR1","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","volume":"175","author":"DE Griffith","year":"2007","unstructured":"Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175:367\u2013416.","journal-title":"Am J Respir Crit Care Med"},{"key":"1384_CR2","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1164\/rccm.201002-0310OC","volume":"182","author":"DR Prevots","year":"2010","unstructured":"Prevots DR, Shaw PA, Strickland D, Jackson LA, Raebel MA, Blosky MA, et al. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med. 2010;182:970\u20136.","journal-title":"Am J Respir Crit Care Med"},{"key":"1384_CR3","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1164\/rccm.201003-0503OC","volume":"182","author":"KL Winthrop","year":"2010","unstructured":"Winthrop KL, McNelley E, Kendall B, Marshall-Olson A, Morris C, Cassidy M, et al. Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease. Am J Respir Crit Care Med. 2010;182:977\u201382.","journal-title":"Am J Respir Crit Care Med"},{"key":"1384_CR4","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1164\/ajrccm.149.5.8173775","volume":"149","author":"RJ Wallace","year":"1994","unstructured":"Wallace RJ, Brown BA, Griffith DE, Girard WM, Murphy DT, Onyi GO, et al. Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease. Am J Respir Crit Care Med. 1994;149:1335\u201341.","journal-title":"Am J Respir Crit Care Med"},{"key":"1384_CR5","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1164\/ajrccm.160.3.9811086","volume":"160","author":"E Tanaka","year":"1999","unstructured":"Tanaka E, Kimoto T, Tsuyuguchi K, Watanabe I, Matsumoto H, Niimi A, et al. Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med. 1999;160:866\u201372.","journal-title":"Am J Respir Crit Care Med"},{"key":"1384_CR6","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1164\/rccm.200603-450OC","volume":"174","author":"DE Griffith","year":"2006","unstructured":"Griffith DE, Brown-Elliott BA, Langsjoen B, Zhang Y, Pan X, Girard W, et al. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2006;174:928\u201334.","journal-title":"Am J Respir Crit Care Med"},{"key":"1384_CR7","first-page":"CD002203","volume":"11","author":"KW Southern","year":"2012","unstructured":"Southern KW, Barker PM, Solis-Moya A, Patel L. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev. 2012;11:CD002203.","journal-title":"Cochrane Database Syst Rev"},{"key":"1384_CR8","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1164\/ajrccm.157.6.9710075","volume":"157","author":"S Kudoh","year":"1998","unstructured":"Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med. 1998;157:1829\u201332.","journal-title":"Am J Respir Crit Care Med"},{"key":"1384_CR9","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1056\/NEJMoa1104623","volume":"365","author":"RK Albert","year":"2011","unstructured":"Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JAD, Criner GJ, et al. COPD Clinical Research Network: azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365:689\u201398.","journal-title":"N Engl J Med"},{"key":"1384_CR10","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1164\/rccm.200801-145OC","volume":"178","author":"TAR Seemungal","year":"2008","unstructured":"Seemungal TAR, Wilkinson TMA, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med. 2008;178:1139\u201347.","journal-title":"Am J Respir Crit Care Med"},{"key":"1384_CR11","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1001\/jama.2013.1937","volume":"309","author":"J Altenburg","year":"2013","unstructured":"Altenburg J, de Graaff CS, Stienstra Y, Sloos JH, van Haren EH, Koppers RJ, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non\u2013cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA. 2013;309:1251\u20139.","journal-title":"JAMA"},{"key":"1384_CR12","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1001\/jama.2013.2290","volume":"309","author":"DJ Serisier","year":"2013","unstructured":"Serisier DJ, Martin ML, McGuckin MA, Lourie R, Chen AC, Brain B, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA. 2013;309:1260\u20137.","journal-title":"JAMA"},{"key":"1384_CR13","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1164\/ajrccm.161.4.16141","volume":"161","author":"American Thoracic Society and the Centers for Disease Control and Prevention","year":"2000","unstructured":"American Thoracic Society and the Centers for Disease Control and Prevention. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med. 2000;161:1376.","journal-title":"Am J Respir Crit Care Med"},{"key":"1384_CR14","volume-title":"Susceptibility testing of mycobacteria, Nocardia, and other aerobic actinomycetes","author":"National Committee for Clinical Laboratory Standards","year":"2011","unstructured":"National Committee for Clinical Laboratory Standards. Susceptibility testing of mycobacteria, Nocardia, and other aerobic actinomycetes. 2nd ed. 2011. Clinical and Laboratory Standards Institute; M24-T2.","edition":"2"},{"key":"1384_CR15","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1164\/rccm.201204-0682OC","volume":"186","author":"J Ingen van","year":"2012","unstructured":"van Ingen J, Egelund EF, Levin A, Totten SE, Boeree MJ, Mouton JW, et al. The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. Am J Respir Crit Care Med. 2012;186:559\u201365.","journal-title":"Am J Respir Crit Care Med"},{"key":"1384_CR16","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1007\/s10156-011-0351-x","volume":"18","author":"Y Kobashi","year":"2012","unstructured":"Kobashi Y, Abe M, Mouri K, Obase Y, Kato S, Oka M. Relationship between clinical efficacy for pulmonary MAC and drug-sensitivity test for isolated MAC in a recent 6-year period. J Infect Chemother. 2012;18:436\u201343.","journal-title":"J Infect Chemother"},{"key":"1384_CR17","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.rmed.2006.04.002","volume":"101","author":"Y Kobashi","year":"2007","unstructured":"Kobashi Y, Matsushima T, Oka M. A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease. Respir Med. 2007;101:130\u20138.","journal-title":"Respir Med"},{"key":"1384_CR18","first-page":"885","volume":"34","author":"The Committee for Classification of Tuberculosis in the Japanese Society for Tuberculosis","year":"1959","unstructured":"The Committee for Classification of Tuberculosis in the Japanese Society for Tuberculosis. The criteria of chest roentgenogram classification of pulmonary tuberculosis established by the Japanese Society for Tuberculosis. Kekkaku. 1959;34:885\u20138.","journal-title":"Kekkaku"},{"key":"1384_CR19","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1164\/rccm.200905-0704OC","volume":"180","author":"K Jeon","year":"2009","unstructured":"Jeon K, Kwon OJ, Lee NY, Kim B-J, Kook Y-H, Lee S-H, et al. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am J Respir Crit Care Med. 2009;180:896\u2013902.","journal-title":"Am J Respir Crit Care Med"},{"key":"1384_CR20","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1097\/QCO.0b013e3283511a64","volume":"25","author":"DE Griffith","year":"2012","unstructured":"Griffith DE, Aksamit TR. Therapy of refractory nontuberculous mycobacterial lung disease. Curr Opin Infect Dis. 2012;25:218\u201327.","journal-title":"Curr Opin Infect Dis"},{"key":"1384_CR21","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.athoracsur.2013.03.008","volume":"96","author":"Y Shiraishi","year":"2013","unstructured":"Shiraishi Y, Katsuragi N, Kita H, Hyogotani A, Saito MH, Shimoda K. Adjuvant surgical treatment of nontuberculous mycobacterial lung disease. Ann Thorac Surg. 2013;96:287\u201391.","journal-title":"Ann Thorac Surg"},{"key":"1384_CR22","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1016\/j.athoracsur.2008.02.041","volume":"85","author":"JD Mitchell","year":"2008","unstructured":"Mitchell JD, Bishop A, Cafaro A, Weyant MJ, Pomerantz M. Anatomic lung resection for nontuberculous mycobacterial disease. Ann Thorac Surg. 2008;85:1887\u201392. discussion 1892\u20133.","journal-title":"Ann Thorac Surg"},{"key":"1384_CR23","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1007\/s10156-011-0303-5","volume":"18","author":"M Fujita","year":"2012","unstructured":"Fujita M, Kajiki A, Tao Y, Miyazaki M, Ouchi H, Harada E, et al. The clinical efficacy and safety of a fluoroquinolone-containing regimen for pulmonary MAC disease. J Infect Chemother. 2012;18:146\u201351.","journal-title":"J Infect Chemother"},{"key":"1384_CR24","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1128\/AAC.02281-12","volume":"57","author":"W-J Koh","year":"2013","unstructured":"Koh W-J, Hong G, Kim S-Y, Jeong B-H, Park HY, Jeon K, et al. Treatment of refractory Mycobacterium avium complex lung disease with a moxifloxacin-containing regimen. Antimicrob Agents Chemother. 2013;57:2281\u20135.","journal-title":"Antimicrob Agents Chemother"},{"key":"1384_CR25","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1093\/clinids\/22.Supplement_1.S3","volume":"22","author":"CM Kunin","year":"1996","unstructured":"Kunin CM. Antimicrobial activity of rifabutin. Clin Infect Dis. 1996;22:S3\u201314.","journal-title":"Clin Infect Dis"},{"key":"1384_CR26","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1093\/infdis\/171.3.747","volume":"171","author":"RJ Wallace","year":"1995","unstructured":"Wallace RJ, Brown BA, Griffith DE, Girard W, Tanaka K. Reduced serum levels of clarithromycin in patients treated with multi-drug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection. J Infect Dis. 1995;171:747\u201350.","journal-title":"J Infect Dis"},{"key":"1384_CR27","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1164\/ajrccm.153.6.8665032","volume":"153","author":"RJ Wallace Jr","year":"1996","unstructured":"Wallace Jr RJ, Brown BA, Griffith DE, Girard WM, Murphy DT. Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients. Am J Respir Crit Care Med. 1996;153:1766\u201372.","journal-title":"Am J Respir Crit Care Med"},{"key":"1384_CR28","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1056\/NEJM199402103300616","volume":"330","author":"SD Shafran","year":"1994","unstructured":"Shafran SD, Desch\u00eanes J, Miller M, Phillips P, Toma E. Uveitis and pseudojaundice during a regimen of clarithromycin, rifabutin, and ethambutol. MAC Study Group of the Canadian HIV Trials Network. N Engl J Med. 1994;330:438\u20139.","journal-title":"N Engl J Med"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-016-1384-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-016-1384-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-016-1384-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-016-1384-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,9,22]],"date-time":"2017-09-22T18:17:50Z","timestamp":1506104270000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-016-1384-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["1384"],"URL":"https:\/\/doi.org\/10.1186\/s12879-016-1384-7","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12]]},"article-number":"31"}}